Hepatocellular Carcinima
Conditions
Interventions
The whole group:Radiotherapy
Sponsors
Peking University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years, gender is not limited; 2. ECOG 0-1 points; 3. Hepatocellular carcinoma confirmed by clinical diagnosis or pathology; 4. Child-pugh score of liver function is A or B (= 90 g/L, ANC >= 1.5 x 10^9/L, PLT >= 75 x 10^9/L, WBC >= 3.0 x 10^9/L; creatinine <= 1.5 x ULN; 8. The liver can be scanned with enhanced MRI within 2 weeks before radiotherapy, and the effect of enhanced MRI can be re-examined 1-3 months after radiotherapy; 9. Patients with active hepatitis B virus (HBV) infection: HBV-deoxyribonucleic acid (DNA) must be < 500 IU/mL (if the research center only has a copy/mL testing unit, it must be < 2500 copy/mL ), and receiving anti-HBV therapy (treatment according to local standard of care, such as entecavir) for at least 14 days prior to the start of study treatment and willing to receive antiviral therapy throughout the study period; Hepatitis C virus (HCV) ribonucleic acid (RNA) positive Patients must receive antiviral therapy according to local standard treatment guidelines and liver function within CTCAE grade 1 elevation; 10. Women of childbearing age (usually 15-49 years old) must have a negative pregnancy test (serum or urine) result within 14 days before enrollment; for men, they should agree to use appropriate methods of contraception during the observation period; 11. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up.
Exclusion criteria
Exclusion criteria: 1. Those who are unable to receive MRI examination or are allergic to gadoxetate disodium; 2. The tumor is close to the organs at risk such as the intestine, and it is difficult to tolerate radiotherapy; the residual liver volume is less than 700ml, and it is difficult to tolerate radiotherapy; 3. Past or current combined with other malignant tumor diseases; 4. Patients with severe cardiopulmonary insufficiency who cannot tolerate radiotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Imagine characteristics; | — |
Countries
China
Contacts
Public ContactWeihu Wang
Peking University Cancer Hospital
Outcome results
None listed